Interview with CEO, Linda Persson, in Privata Affรคrer

๐ƒ๐จ ๐ฒ๐จ๐ฎ ๐ฐ๐š๐ง๐ญ ๐ญ๐จ ๐ค๐ง๐จ๐ฐ ๐ฆ๐จ๐ซ๐ž ๐š๐›๐จ๐ฎ๐ญ ๐๐š๐ง๐จ๐„๐œ๐ก๐จโ€™๐ฌ ๐ข๐ง๐ง๐จ๐ฏ๐š๐ญ๐ข๐ฏ๐ž ๐๐ข๐š๐ ๐ง๐จ๐ฌ๐ญ๐ข๐œ ๐ฆ๐ž๐ญ๐ก๐จ๐ ๐š๐ง๐ ๐ญ๐ก๐ž ๐จ๐ง๐ ๐จ๐ข๐ง๐  ๐ฌ๐ก๐š๐ซ๐ž ๐ข๐ฌ๐ฌ๐ฎ๐ž?

Don’t miss the interview with our CEO, Linda Persson, in Privata Affรคrer. NanoEcho is currently conducting a new share issue to enter the clinical phase with our patented diagnostic method, which aims to improve healthcare by providing patients with a more accurate diagnosis and personalised treatment.

โ€“ With our new patented technology, we aim to prevent unnecessary surgeries for patients, reducing their suffering while generating significant health-economic benefits, both within healthcare and in society as a whole, says Linda Persson, CEO of NanoEcho.

Read the full article: https://lnkd.in/dfZjkw56

Learn more about the ongoing share issue: https://lnkd.in/dH_uUs5h

NanoEchoโ€™s innovative method, with its high precision, aims to facilitate the differentiation between diseased and healthy tissue and at the same time determine a more precise localization of cancerous tissue. The goal is to provide a more reliable diagnosis of, for example cancer diseases, that has the potential to contribute to cost-effectiveness in the health care.

Not For Sale โ€“ For Clinical Investigation Use Only – EU Trial No.: 2024-515335-29-00

NanoEcho AB
Scheelevรคgen 19,
223 63 Lund
info@nanoecho.se

Facebook Linkedin Youtube Envelope
Copyright 2024 NanoEcho ยฉ All Rights Reserved.
Privacy policy